No Detail Found!

Factors Associated with Ischaemic Stroke Development Despite Oral Anticoagulant Therapy in Patients with Non-Valvular Atrial Fibrillation

Author(s)
Emre Ozdemir Department of Cardiology, Ataturk Research and Training Hospital, Izmir Katip Celebi University,Izmir,Turkiye
Muhammed Mucahit Tiryaki Department of Cardiology, Mus Government Hospital,Mus,Turkiye
Zeynep Emren Department of Cardiology, Cigli Research and Training Hospital, Bakircay University,Izmir,Turkiye
Ozgen Safak Department of Cardiology, Faculty of Medicine, Balikesir University,Balikesir,Turkiye
Enise Tiryaki Department of Neurology, Mus Government Hospital,Mus,Turkiye
Aysen Suzen Ekinci Department of Neurology, Ataturk Research and Training Hospital,Izmir,Turkiye
Abstract
To evaluate the e ectiveness of the most popular risk scores (CHADS2, CHA2DS2-VASc, and ATRIA scores) in predicting stroke events in patients with non-valvular atrial brillation (NVAF) who were already receiving oral anticoagulant therapy (OAT). Study Design: An observational study. Place and Duration of the Study: Department of Cardiology, Ataturk Research and Training Hospital, Izmir Katip Celebi University, Izmir, Turkiye, from January 2020 to December 2023. Methodology: Patients with NVAF who were on OAT were divided into two groups. Group 1 consisted of patients who had not experienced a stroke while on OAT, and Group 2 consisted of patients who had experienced at least one stroke while on OAT at the time of inclusion. Continuous variables were presented as mean or median values and were compared using Student s t-test or Mann-Whitney U test, depending on the type of data distribution. Results: There were 162 patients in Group 1 and 129 patients in Group 2, the majority being females. The median age of patients was 76 years (IQR: 71-82) in Group 1 and 75 years (IQR: 68-81) in Group 2. Comorbidities were statistically similar in both groups except for hyperlipidemia. Treatment for atrial brillation (AF) was also statistically similar in both groups. The CHA2DS2-VASc and ATRIA stroke scores showed statistically signi cant di erences between the groups. In univariate analysis, hyperlipidemia and ATRIA stroke score were >8, and in multivariate analysis, only ATRIA stroke score was >8, which showed a correlation with estimating the risk of ischaemic stroke (IS) events under oral anticoagulation (OAC). The ATRIA stroke score showed a strong correlation Spearman s rho test and in the ROC curve. Conclusion: The CHA2DS2-VASc, CHADS, and ATRIA risk scores have proven e ective in primary IS prophylaxis. The ATRIA stroke score system for secondary prevention appears to be more e ective than the most popular score systems.
Publication Details
Page(s) 712-716
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 06, Year: 2025

Request the full text from PASTIC

Keywords
CHA2DS2-VASC, Oral anticoagulation, Ischaemic stroke, Non-valvular atrial brillation, ATRIA stroke score
References
Tsao CW,Aday AW,Almarzooq ZI,Alonso A,Beaton AZ,Bittencourt MS .2022 .. Heart disease and stroke statistics-2022 update: A report from the American Heart Association. Circulation, 10(8) : e153-639.
Meinel TR,Branca M,De Marchis GM,Nedeltchev K,Kahles T,Bonati L .2021 .Prior anticoagulation in patients with ischaemic stroke and atrial brillationA. nn Neurol, 10(1) : 42-53.
Yaghi S,Liberman AL,Henninger N,Grory BM,Nouh A,Scher E .2020 .Factors associated with therapeutic anticoagulation status in patients with ischaemic stroke and atrial brillation. J Stroke Cerebrovasc, 10(7) : 104888.
Yu I,Song TJ,Kim BJ,Heo SH,Jung JM,Oh KM .2021 .Essen stroke risk scores in stroke with atrial brillation: A nationwide multicentre registry study. Medicine, 10(3) : CHA2DS2.
Aspberg S,Chang Y,Atterman A,Bottai M,Go AS,Singer DE .2016 .Comparison of the ATRIA, CHADS2, and CHA2DS2 VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial brillation. Eur Heart J, 10(42) : 3203-10.
Levey AS,Stevens LA,Schmid CH,Zhang YL,Castro AF,Feldman HI .2009 .A new equation to estimate glomerular ltration rate. Ann Intern Med, 10(9) : 200905050-12.
Zhao S,Hong X,Cao J,Cai H,Du S .2020 .Appropriate dosing regimens of non-vitamin K antagonist oral anticoagulants for treatment of patients with non-valvular atrial brillation: An evidence-based considerationF. ront Pharmacol, 01293 : 1293.
Singer DE,Chang Y,Borowsky LH,Fang MC,Pomernacki NK,Udaltsova N .2013 .A new risk scheme to predict ischaemic stroke and other thromboembolism in atrial brillation: The ATRIA study stroke risk score. J Am Heart Assoc, 10(3) : .
.2016 .warfarin in nonvalvular atrial brillation. J Am Heart Assoc, 10(6) : .
Hart RG,Pearce LA,Aguilar MI .2007 .Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial brillation. Ann Intern Med, 10(12) : 0003-67.
Ru CT,Giugliano RP,Braunwald E,Ho man EB,Deenadayalu N,Ezekowitz MD .2014 .Comparison of the e cacy and safety of new oral anticoagulants with warfarin in patients with atrial brillation: A meta-analysis of randomised trials. Lancet, 6736(13) : 62343-0.
Khanevski AN,Bjerkreim AT,Novotny V,Naess H,Thomassen L,Logallo N .2019 .Recurrent ischaemic stroke: Incidence, predictors, and impact on mortality. Acta Neurol Scand, 10(1) : 3-8.
Kocaman G,Duruyen H,Kocer A,Talip . .2015 .ARecurrent ischaemic stroke characteristics and assessment of su ciency of secondary stroke prevention. Noro Psikiyatr Ars, 7499(2) : 139.
Hindricks G,Potpara T,Dagres N,Arbelo E,Bax JJ,Blomstrom-Lundqvist C,Eriksson SE,Olsson JE .2021 .EHRA) of the ESC. Eur Heart J, 10(5) : 373-498.
Mohan KM,Wolfe CD,Rudd AG,Heuschmann PU,Kolominsky Rabas PL,Grieve AP .2011 .Risk and cumulative risk of stroke recurrence: A systematic review and metaanalysis. Stroke, 10(5) : 1489-94.
Martins RP,Galand V,Colette E,Behar N,Pavin D,Leclercq C .2016 .De ning nonvalvular atrial brillation: A quest for clari cation. Am Heart J, 05 : 161-7.
Giancaterino S,Hsu J .2019 .Valvular atrial brillation: A confusing and obsolete de nition. J Am Coll, 04(25) : 3360-1.
Chugh SS,Havmoeller R,Narayanan K,Singh D,Rienstra M,Benjamin EJ .2014 .of atrial brillation: A global burden of disease 2010 study. Circulation, 113(8) : 837-47.
Yao X,Abraham NS,Sangaralingham LR,Bellolio MF,McBane RD,Shah ND,Noseworthy PA ND . .E ectiveness and safety of dabigatran, rivaroxaban, and apixabanversus. , : .
Kolmos M,Christo L,Kruuse C .2021 .Recurrent ischaemic stroke A systematic review and meta-analysis. J Stroke Cerebrovasc Dis, 105935(8) : 105935.
van Den Ham HA,Klungel OH,Singer DE,Leufkens HG,van Staa TP. .2015 .Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial brillation: Results from a national primary care database. J Am Coll Cardiol, 08(17) : 1851-9.
Paciaroni M,Agnelli G,Caso V,Silvestrelli G,Sei ge DJ,Engelter S .2019 .Causes and risk factors of cerebral 1schaemic events in patientswith atrial brillation treated with non-vitamin k antagonist oral anticoagulants for stroke prevention. Stroke, 10(8) : 2168-74.
0

Citations

0

Downloads

32

Views